Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves

被引:29
作者
Vargas-Estrada, D. [1 ]
Gracia-Mora, J. [2 ]
Sumano, H. [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Dept Fisiol & Farmacol, Fac Med Vet & Zootecn, Mexico City 04510, DF, Mexico
[2] Univ Nacl Autonoma Mexico, Dept Quim Inorgan, Fac Quim, Mexico City 04510, DF, Mexico
关键词
doxycycline; calves; pharmacokinetic; sustained-release;
D O I
10.1016/j.rvsc.2007.07.003
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Doxycycline hyclate (DOX-h) can be regarded as a time-dependant antibacterial. Hence, a parenteral long-acting formulation may be regarded as more pharmacologically sound. A poloxamer-based matrix was used to produce a long-acting injectable preparation (DOX-h-LA) and its serum concentrations vs. time profile investigated after its s.c. injection to calves. Serum concentrations profiles for such a prepartion were compared to the corresponding profiles obtained with an aqueous formulation of DOX-h injected either i.m. or i.v. in 10 calves in a crossover study at dose of 10 mg/kg, with washout periods. DOX-h-LA showed the greatest values for bioavailability (602%); maximum serum concentration (C(max)) value was 1.99 mu g/mL with a time to reach C(max) (T(max)) of 25 h and an elimination half-life of 40.81 h. Considering minimum effective serum concentration of 0.5 mu g/mL a dose-interval of 80 h can be achieved for DOX-h-LA, and only 9.7 h and 17 h after the i.v. or i.m. administration of DOX-h, respectively. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:477 / 482
页数:6
相关论文
共 39 条
[1]  
ABD AM, 2004, PHARM RES, V49, P487
[2]   Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia [J].
Ailani, RK ;
Agastya, G ;
Ailani, RK ;
Mukunda, BN ;
Shekar, R .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (03) :266-270
[3]  
ARONSON AL, 1980, J AM VET MED ASSOC, V176, P1061
[4]   CYCLODEXTRINS IN THE PHARMACEUTICAL FIELD [J].
BEKERS, O ;
UIJTENDAAL, EV ;
BEIJNEN, JH ;
BULT, A ;
UNDERBERG, WJM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (11) :1503-1549
[5]   SIMPLIFIED ACCURATE METHOD FOR ANTIBIOTIC ASSAY OF CLINICAL SPECIMENS [J].
BENNETT, JV ;
BRODIE, JL ;
BENNER, EJ ;
KIRBY, WMM .
APPLIED MICROBIOLOGY, 1966, 14 (02) :170-&
[6]  
Boxenbaum H, 1998, J Pharm Pharm Sci, V1, P90
[7]   In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones [J].
Brook, I ;
Elliott, TB ;
Pryor, HI ;
Sautter, TE ;
Gnade, BT ;
Thakar, JH ;
Knudson, GB .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (06) :559-562
[8]   THE TETRACYCLINES - PROSPECTS AT THE BEGINNING OF THE 1980S [J].
CHOPRA, I ;
HOWE, TGB ;
LINTON, AH ;
LINTON, KB ;
RICHMOND, MH ;
SPELLER, DCE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 8 (01) :5-21
[9]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[10]   DOXYCYCLINE [J].
CUNHA, BA ;
SIBLEY, CM ;
RISTUCCIA, AM .
THERAPEUTIC DRUG MONITORING, 1982, 4 (02) :115-135